Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 359,296 shares at $2.68 ($950K) on 2023-08-01, disclosed to the SEC on 2023-08-03.
Scheduled sale ($950k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.68 | 105,944 | $284K | 29.9% |
| 2 | $2.68 | 105,944 | $284K | 29.9% |
| 3 | $2.59 | 73,704 | $191K | 20.1% |
| 4 | $2.59 | 73,704 | $191K | 20.1% |
| Total | $2.64 avg | 359,296 | $950K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |